Morolimumab Biosimilar Monoclonal Antibody (RhD) for Research

Cat No.: GMP-Bios-INN-918

Anti-RHD therapeutic antibody (Pre-made Morolimumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Morolimumab is a human monoclonal antibody against the human Rhesus factor.[1][2]

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-918-1mg 1mg 3090
GMP-Bios-INN-918-10mg 10mg
GMP-Bios-INN-918-100mg 100mg
GMP-Bios-INN-918-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Morolimumab Biosimilar, Whole Mab, Anti-Rhd Antibody: Anti-CD240D/DIIIc/HDFNRH/RH/RH30/RHCED/RHDVA(TT)/RHDel/RHPII/RHXIII/Rh4/RhDCw/RhII/RhK562-II/RhPI therapeutic antibody
INN Name Morolimumab
TargetRHD
FormatWhole mAb
Derivationhuman
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies0
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0



About target - RHD

1. Protein Blood group Rh(D) polypeptide

2. Gene RHD

3. Organism Homo sapiens (Human)

Function
May be part of an oligomeric complex which is likely to have a transport or channel function in the erythrocyte membrane.